Oneness Biotech Co Ltd (4743) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.001x

Based on the latest financial reports, Oneness Biotech Co Ltd (4743) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$14.32 Million ≈ $451.28K USD) by net assets (NT$10.97 Billion ≈ $345.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 4743 stock market capitalisation for the company's overall valuation and market capitalisation.

Oneness Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Oneness Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Oneness Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Oneness Biotech Co Ltd ranked by their cash flow conversion efficiency. Explore 4743 cash flow quality score to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Kunshan Top A Intelligent Equipment
SHE:300836
-0.017x
Baida Group Co Ltd
SHG:600865
0.003x
Phenix Optical Co Ltd
SHG:600071
0.083x
Jai Balaji Industries Limited
NSE:JAIBALAJI
0.060x
Center Laboratories
TWO:4123
0.002x
Beijing Thunisoft Co Ltd
SHE:300271
-0.037x
Daishin Sec
KO:003540
-0.415x
Bank of Kaohsiung Ltd
TW:2836
-0.099x

Annual Cash Flow Conversion Efficiency for Oneness Biotech Co Ltd (2009–2024)

The table below shows the annual cash flow conversion efficiency of Oneness Biotech Co Ltd from 2009 to 2024. View today's stock price for Oneness Biotech Co Ltd for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 NT$12.80 Billion
≈ $403.27 Million
NT$-345.58 Million
≈ $-10.89 Million
-0.027x +0.94%
2023-12-31 NT$14.50 Billion
≈ $456.74 Million
NT$-395.13 Million
≈ $-12.45 Million
-0.027x +53.97%
2022-12-31 NT$14.88 Billion
≈ $468.80 Million
NT$-881.00 Million
≈ $-27.76 Million
-0.059x -188.75%
2021-12-31 NT$14.09 Billion
≈ $443.89 Million
NT$-288.89 Million
≈ $-9.10 Million
-0.021x -278.41%
2020-12-31 NT$13.76 Billion
≈ $433.50 Million
NT$158.14 Million
≈ $4.98 Million
0.011x +134.81%
2019-12-31 NT$6.46 Billion
≈ $203.48 Million
NT$-213.25 Million
≈ $-6.72 Million
-0.033x -1295.85%
2018-12-31 NT$2.17 Billion
≈ $68.23 Million
NT$-5.12 Million
≈ $-161.40K
-0.002x +96.43%
2017-12-31 NT$2.49 Billion
≈ $78.60 Million
NT$-165.27 Million
≈ $-5.21 Million
-0.066x -54.05%
2016-12-31 NT$2.52 Billion
≈ $79.53 Million
NT$-108.54 Million
≈ $-3.42 Million
-0.043x +16.46%
2015-12-31 NT$2.77 Billion
≈ $87.13 Million
NT$-142.34 Million
≈ $-4.48 Million
-0.051x +34.05%
2014-12-31 NT$1.93 Billion
≈ $60.95 Million
NT$-150.98 Million
≈ $-4.76 Million
-0.078x -71.90%
2013-12-31 NT$1.97 Billion
≈ $61.94 Million
NT$-89.26 Million
≈ $-2.81 Million
-0.045x -364.04%
2012-12-31 NT$1.40 Billion
≈ $44.26 Million
NT$24.15 Million
≈ $760.95K
0.017x +180.32%
2011-12-31 NT$1.37 Billion
≈ $43.07 Million
NT$-29.27 Million
≈ $-922.04K
-0.021x -115.21%
2010-12-31 NT$1.09 Billion
≈ $34.31 Million
NT$153.25 Million
≈ $4.83 Million
0.141x +252.19%
2009-12-31 NT$1.11 Billion
≈ $34.86 Million
NT$-102.30 Million
≈ $-3.22 Million
-0.092x --

About Oneness Biotech Co Ltd

TWO:4743 Taiwan Biotechnology
Market Cap
$687.33 Million
NT$21.82 Billion TWD
Market Cap Rank
#10813 Global
#371 in Taiwan
Share Price
NT$45.60
Change (1 day)
+2.13%
52-Week Range
NT$41.15 - NT$76.70
All Time High
NT$395.32
About

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, an innovative wound care medical device. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase II… Read more